Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Lu AG09222 for the Prevention of Migraine in Patients With Unsuccessful Prior Preventive Treatments
Latest Information Update: 09 Feb 2024
At a glance
- Drugs LU AG09222 (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Acronyms HOPE
- Sponsors Lundbeck A/S
- 14 Sep 2023 According to H. Lundbeck A/S media release, the company announced the data from this study at the International Headache Congress (IHC) 2023 in Seoul, Korea.
- 14 Sep 2023 Primary endpoint (Change From Baseline in the Number of Monthly Migraine Days (MMDs) at Month 1 (Weeks 1-4)) has been met.
- 14 Sep 2023 Results published in H. Lundbeck A/S media release.